The Company’s wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.

Type
Public
HQ
Boulder, US
Founded
1998
Size (employees)
209 (est)
Array BioPharma was founded in 1998 and is headquartered in Boulder, US
Report incorrect company information

Key People/Management at Array BioPharma

Ron Squarer

Ron Squarer

Chief Executive Officer
Jason Haddock

Jason Haddock

Chief Financial Officer
Andrew Robbins

Andrew Robbins

Chief Operating Officer
Victor Sandor

Victor Sandor

Chief Medical Officer
NICHOLAS SACCOMANO

NICHOLAS SACCOMANO

Chief Scientific Officer
Curtis Oltmans

Curtis Oltmans

Executive Vice President, General Counsel and Secretary
Show more

Array BioPharma Office Locations

Array BioPharma has offices in Boston, Charlotte, Phoenix, Detroit and in 7 other locations
Boulder, US (HQ)
3200 Walnut St
Cambridge, US
301 125 Cambridge Park Dr
Morrisville, US
115 3005 Carrington Mill Blvd
Show all (11)
Report incorrect company information

Array BioPharma Financials and Metrics

Array BioPharma Financials

Array BioPharma's revenue was reported to be $137.88 m in FY, 2016 which is a 165.6% increase from the previous period.
USD

Revenue (Q1, 2018)

29.7 m

Net income (Q1, 2018)

(38 m)

EBIT (Q1, 2018)

(35.5 m)

Market capitalization (20-Apr-2018)

2.8 b

Cash (30-Jun-2016)

56.6 m
Array BioPharma's current market capitalization is $2.8 b.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

42.1 m51.9 m137.9 m

Revenue growth, %

23%166%

EBIT

(75.6 m)3.3 m(82.2 m)

EBIT margin, %

(180%)6%(60%)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

35.4 m43 m39.3 m44.5 m33.3 m29.7 m

General and administrative expense

9.9 m8.4 m7.9 m8.8 m11.7 m12 m

Operating expense total

57 m63.1 m63.3 m64.3 m65.2 m65.3 m

EBIT

(21.5 m)(20 m)(24 m)(19.8 m)(31.9 m)(35.5 m)
Annual
USDFY, 2014FY, 2015FY, 2016

Cash

68.6 m55.7 m56.6 m

Accounts Receivable

5.4 m6.3 m39.3 m

Inventories

5.2 m6.4 m6.1 m

Current Assets

121.7 m191 m155.3 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016

Cash

65 m47.2 m52.2 m46.8 m68.1 m141.5 m56.4 m

Accounts Receivable

1 m5.7 m4.4 m6 m4.9 m2.1 m13.5 m

Current Assets

134.2 m128.5 m118.1 m122.8 m150.8 m196.6 m179.6 m

PP&E

9.1 m8.4 m7.8 m7.8 m8.1 m7.5 m5 m
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

(85.3 m)9.4 m(92.8 m)

Depreciation and Amortization

4.5 m3.7 m1.5 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

(15.7 m)(32.1 m)(57 m)(27.6 m)(36.2 m)22.1 m(21 m)(24.2 m)(22.7 m)(28.6 m)(23.3 m)(35.3 m)

Depreciation and Amortization

1.1 m2.4 m3.6 m876 k1.8 m2.8 m473 k

Accounts Payable

12.1 m15.6 m5.9 m6.5 m7.8 m8.9 m

Cash From Operating Activities

(1.1 m)(34.3 m)(49.4 m)(18.8 m)(16.8 m)21.5 m(19.2 m)
USDY, 2017

Revenue/Employee

142.3 k
Show all financial metrics
Report incorrect company information